1.Sampaio, C. Alzheimer disease: disease modifying trials; where are we? Where do we need to go? A reflective paper. J Nutr Health Aging. 2006;10(2):113–115.
2.Mani, RB. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Stat Med. 2004;23(2):305–314.
3.Cummings, JL. Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. Alzheimers Dement. 2006;2(4):263–271.
4.Games, D, Adams, D, Alessandrini, R, et, al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 1995;373(6514):523–527.
5.Holcomb, L.Gordon, MN, McGowan, E, et al.Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998;4(1):97–100.
6.Lewis, PA, Piper, S, Baker, M, et al.Expression of BRI–amyloid β peptide fusion proteins: a novel method for specific high-level expression of amyloid β peptides. Biochim Biophys Acta. 2001;1537(1):58–62.
7.Lewis, J, McGowan, E, Rockwood, J, et al.Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25(4):402–405.
8.Oddo, S, Caccamo, A, Shepherd, JD, et al.Triple-transgenic model of Alzheimer's disease with plaques and tangles: intraceliular Aβ and synaptic dysfunction. Neuron. 2003;39(3):409–421.
9.Golde, TE. The Aβ hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol. 2005;15(1):84–87.
10.Cummings, JL, Cole, G. Alzheimer disease. JAMA. 2002;287(18):2335–2338.
11.Zhu, CW, Scarmeas, N, Torgan, R, et al.Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease. Neurology. 2006;67(6):998–1005.
12.Zhu, CW, Scarmeas, N, Torgan, R, et al.Clinical features associated with costs in early AD: baseline data from the Predictors Study. Neurology. 2006;66(7):1021–1028.
13.Brookmeyer, R, Gray, S, Kawas, C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88(9):1337–1342.
14.Pollack, SJ, Lewis, H. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease. Curr Opin Investig Drugs. 2005;6(1):35–47.
15.Wong, GT, Manfra, D, Poulet, FM, et al.Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004;279(13):12876–12882.
16.Morihara, T, Chu, T, Ubeda, O, Beech, W, Cole, GM. Selective inhibition of Aβ42 production by NSAID R-enantiomers. J Neurochem. 2002;83(4):1009–1012.
17.Wilcock, GK, Black, SE, Haworth, J, et al.Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective Aβ42-lowering agent, in Alzheimer's disease (AD): results of a 12-month phase 2 trial and 1-year follow-on study. Alzheimers Dement. 2006;2(3 suppl 1):S81–S82.
18.Aisen, PS, Saumier, D, Briand, R, et al.A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease. Neurology. 2006;67(10):1757–1763.
19.Neurochem announces results from tramiprosate (ALZHEMED™) North American Phase III clinical trial. Laval, Quebec: Neurochem Inc.: August 26, 2007.
20.Transition Therapeutics announces completion of Phase I clinical studies with Alzheimer's disease drug candidate ELND-005/AZD-103. Toronto, Ontario: Transition Therapeutics Inc.; August 30, 2007.
21.Boche, D, Nicoll, JA, Weller, RO. Immunotherapy for Alzheimer's disease and other dementias. Curr Opin Neurol. 2005;18(6):720–725.
22.Schenk, D, Barbour, R, Dunn, W, et al.Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173–177.
23.Bayer, AJ, Bullock, R, Jones, RW, et al.Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology. 2005;64(1):94–101.
24.Hock, C, Konietzko, U, Streffer, JR, et al.Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003;38(4):547–554.
25.Nicoll, JAR, Wilkinson, D, Holmes, C, Steart, P, Markham, H, Weller, RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med. 2003;9(4):448–452.
26.Solomon, B. Intravenous immunoglobulin and Alzheimer's disease immunotherapy. Curr Opin Mol Ther. 2007;9(1):79–85.
27.Dodel, RC, Du, Y, Depboylu, C, et al.Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004;75(10):1472–1474.
28.Pfizer and TransTech Pharma enter into agreement for the development and commercialization of RAGE modulators. New York, NY: Pfizer Inc.; September 18, 2006.
29.Geroldi, D, Falcone, C, Emanuele, E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem. 2006;13(17):1971–1978.
30.Lee, VM, Trojanowski, JQ. Neurodegenerative tauopathies: human disease and transgenic mouse models. Neuron. 1999;24(3):507–510.
31.Cole, G. A transgenic triple scores a home run. Nat Med. 2006;12(7):762–763.
32.Haroutunia, V, Davies, P, Vianna, C, Buxbaum, JD, Purohit, DP. Tau protein abnormalities associated with the progression of Alzheimer disease type dementia. Neurobiol Aging. 2007;28(1):1–7.
33.Hrnkova, M, Zilka, N, Minichova, Z, Koson, P, Novak, M. Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats. Brain Res. 2007;1130(1):206–213.
34.Roberson, ED, Scearce-Levie, K, Palop, JJ, et al.Reducing endogenous tau ameliorates amyloid β–induced deficits in an Alzheimer's disease mouse model. Science. 2007;316(5825):750–754.
35.DeKosky, ST. Pathology and pathways of Alzheimer's disease with an update on new developments in treatment. J Am Geriatr Soc. 2003;51(5 suppl dementia):S314–S320.
36.Arnaud, L, Robakis, NK, Figueiredo-Pereira, ME. It may take inflammation, phosphorylation and ubiquitination to “tangle” in Alzheimer's disease. Neurodegener Dis. 2006;3(6”:313–319.
37.Jick, H, Zornberg, GL, Jick, SS, Seshadri, S, Drachman, DA. Statins and the risk of dementia. Lancet. 2000;356(9242):1627–1631.
38.Fillit, HM. The role of hormone replacement therapy in the prevention of Alzheimer disease. Arch Intern Med. 2002;162(17):1934–1942.
39.Morris, MC, Evans, DA, Bienias, JL, et al.Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA. 2002;287(24):3230–3237.
40.Oken, BS, Storzbach, DM, Kaye, JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol. 1998;55(11):1409–1415.
41.Frank, B, Gupta, S. A review of antioxidants and Alzheimer's disease. Ann Clin Psychiatry. 2005;17(4):269–286.
42. in t' Veld, BA, Ruitenberg, A, Hofman, A, et al.Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001;345(21):1515–1521.
43.Nordberg, A, Hellström-Lindahl, E, Lee, M, et al.Chronic nicotine treatment reduces β-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). J Neurochem. 2002;81(3):655–658.
44.Dickson, DW. Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: cause or effect? J Clin Invest. 2004;114(1):23–27.
45.Lad, SP, Neet, KE, Mufson, EJ. Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. Curr Drug Targets CNS Neurol Disord. 2003;2(5):315–334.
46.Tuszynski, MH, Thal, L, Pay, M, et al.A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005;11(5):551–555.
47.Pradines, A, Magazin, M, Schiltz, P, Le Fur, G, Caput, D, Ferrara, P. Evidence for nerve growth factor-potentiating activities of the nonpeptidic compound SR 57746A in PC12 cells. J Neurochem. 1995;64(5):1954–1964.
48.Fournier, J, Boutot, G, Keane, PE, Maffrand, JP, Le Fur, G, Soubrié, P. The non-peptide neuroprotective agent SR 57746A interacts with neurotrophin-3 to induce differentiation in the PC12 cell-line. J Pharm Pharmacol. 1998;50(3):323–327.
49.Labie, C, Lafon, C, Marmouget, C, et al.Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex. Br J Pharmacol. 1999;127(1):139–144.
50.Fournier, J, Steinberg, R, Gauthier, T, et al.Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates. Neuroscience. 1993;55(3):629–641.
51.Lemaire, L, Fournier, J, Ponthus, C, et al.Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats. Invest Radiol. 2002;37(6):321–327.
52.Terranova, JP, Kan, JP, Storme, JJ, Perreaut, P, Le Fur, G, Soubrié, P. Administration of amyloid β-peptides in the rat medial septum causes memory deficits: reversal by SR 57746A, a non-peptide neurotrophic compound. Neurosci Lett. 1996;213(2):79–82.
55.Dubois, B, Feldman, HH, Jacova, C, et al.Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734–746.